PACAP application improves functional outcome of chronic retinal ischemic injury in rats-evidence from electroretinographic measurements.
Retinoprotective effects of pituitary adenylate cyclase activating polypeptide (PACAP) are well-known and have been demonstrated in various pathological conditions, such as diabetic retinopathy, excitotoxic retinal injury, UV light-induced degeneration, and ischemic retinal lesion. The neuronal degeneration observed in the different retinal layers under the above pathological conditions can be successfully decreased by PACAP; however, whether this morphological improvement is also reflected in functional amelioration remains unknown. Therefore, our purpose was to investigate the protective effect of PACAP on the rat retina after bilateral common carotid artery occlusion (BCCAO) with electroretinography (ERG) to parallel the functional data with the previous morphological and neurochemical observations. Control eyes received saline treatment while PACAP was injected into the vitreous space of the other eye immediately after the induction of ischemia. Retinal damage and protective effects of PACAP were quantified by the changes in the wave forms and amplitudes. On postoperative days 2 and 14, several parameters were assessed with special attention to the changes of b wave. The results confirm that the previously described morphological protection induced by PACAP treatment is reflected in functional improvement in ischemic retinal lesions.
Department of Anatomy, MTA-PTE "Lendulet" PACAP Research Team, University of Pecs, Szigeti u 12, Pecs, 7624, Hungary.
Bese
B
Danyadi
Krisztina
K
Szabadfi
Dora
D
Reglodi
Agoston
A
Mihalik
Tibor
T
Danyadi
Zsolt
Z
Kovacs
Istvan
I
Batai
Andrea
A
Tamas
Peter
P
Kiss
Gabor
G
Toth
Robert
R
Gabriel
D000818:Animals; D004596:Electroretinography; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000188:drug therapy*; D012160:Retina / Q000187:drug effects* / Q000293:injuries / Q000503:physiopathology; D012164:Retinal Diseases / Q000188:drug therapy*
D051219:Pituitary Adenylate Cyclase-Activating Polypeptide